Tissue Engineering Market Size To Reach $43.13 Billion By 2030

Tissue Engineering Market Growth & Trends

The global tissue engineering market size is estimated to reach USD 43.13 billion by 2030, growing at an estimated CAGR of 14.28% from 2023 to 2030, according to a new report by Grand View Research, Inc. Growing incidence of chronic diseases, such as cardiovascular diseases, diabetes, and orthopedic disorders, has driven the demand for tissue engineering solutions that can repair or replace damaged tissues. Advances in biomaterials, 3D bioprinting, stem cell research, and gene editing techniques have propelled the field of tissue engineering, enabling the development of complex and functional tissues.

The allogeneic tissue transplant method effectively addresses the challenges and limitations associated with the use and accessibility of autologous transplants. In addition, the advancement of specialized procedures, such as implant fixing and sterilization, aimed at converting allogeneic implants into biostatic implants, is anticipated to boost revenue generation in this market.

Tissue regeneration technology is gaining popularity due to its effective products and low rejection rates, leading to an increase in regeneration treatments. Pre-clinical research is currently focused on the use of tissue-engineered vascular grafts in cardiovascular surgery and treatment. Moreover, tissue-engineered bladders can now be successfully implanted outside of the patient's body. Despite these advancements, the market's growth is hindered by challenges such as the high cost of product development and ethical concerns surrounding stem cell research and tissue-engineered products.

 Request a free sample copy or view report summary: Tissue Engineering Market Report

Tissue Engineering Market Report Highlights

• In terms of application, the orthopedics, musculoskeletal, and spine segment held the largest revenue share of 59.76% in 2022 owing to the rising prevalence of musculoskeletal disorders. Tissue engineering has emerged as a crucial therapy option for orthopedic surgeons in the management of several musculoskeletal disorders, ranging from meniscal deficits in young athletes to osteochondral abnormalities in the glenohumeral joint

• The cardiology & vascular segment is anticipated to grow at the fastest CAGR of 25.94% over the forecast period, owing to a rapid increase in the prevalence of cardiovascular disorders globally

• For the past two decades, cardiac cell therapy or cardiomyoplasty has been a significant focal point in the majority of studies aimed at managing heart disease through regeneration

• The increasing prevalence of children with congenital malformations, including single ventricle anomalies, has resulted in a rising demand for heart transplantation

• In terms of region, North America held the largest revenue share of 51.23% in 2022 due to a rise in awareness for stem cell therapy as well as a growing geriatric population

• Asia Pacific is anticipated to grow at the fastest CAGR of 15.84% over the forecast period due to the presence of untapped opportunities in the emerging economies of China and India

Tissue Engineering Market Segmentation

Grand View Research has segmented the global tissue engineering market based on application and region:

Tissue Engineering Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Cord Blood & Cell Banking

• Cancer

• GI, Gynecology

• Dental

• Skin & Integumentary

• Urology

• Orthopedics, Musculoskeletal, & Spine

• Neurology

• Cardiology & Vascular

• Others

Tissue Engineering Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players in the Tissue Engineering Market

• Zimmer Biomet Holdings, Inc.

• AbbVie (Allergan)

• Becton Dickinson and Company

• B. Braun

• Integra LifeSciences Corporation

• Organogenesis Holdings Inc.

• Medtronic

• ACell, Inc.

• Athersys, Inc.

• Tissue Regenix Group plc

• Stryker Corporation

• RTI Surgical, Inc.

• ReproCell, Inc.

• Baxter International, Inc.